REGENXBIO Statistics
Total Valuation
REGENXBIO has a market cap or net worth of $455.64 million. The enterprise value is $359.19 million.
Important Dates
The last earnings date was Thursday, August 7, 2025, before market open.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
REGENXBIO has 50.51 million shares outstanding. The number of shares has increased by 10.99% in one year.
| Current Share Class | 50.51M |
| Shares Outstanding | 50.51M |
| Shares Change (YoY) | +10.99% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 7.99% |
| Owned by Institutions (%) | 76.35% |
| Float | 41.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.90 |
| Forward PS | 1.86 |
| PB Ratio | 2.08 |
| P/TBV Ratio | 2.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.31 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.13, with a Debt / Equity ratio of 1.27.
| Current Ratio | 3.13 |
| Quick Ratio | 3.03 |
| Debt / Equity | 1.27 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.52 |
Financial Efficiency
Return on equity (ROE) is -62.49% and return on invested capital (ROIC) is -20.73%.
| Return on Equity (ROE) | -62.49% |
| Return on Assets (ROA) | -17.88% |
| Return on Invested Capital (ROIC) | -20.73% |
| Return on Capital Employed (ROCE) | -35.67% |
| Revenue Per Employee | $441,309 |
| Profits Per Employee | -$497,368 |
| Employee Count | 353 |
| Asset Turnover | 0.27 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -23.34% in the last 52 weeks. The beta is 1.11, so REGENXBIO's price volatility has been higher than the market average.
| Beta (5Y) | 1.11 |
| 52-Week Price Change | -23.34% |
| 50-Day Moving Average | 8.54 |
| 200-Day Moving Average | 8.27 |
| Relative Strength Index (RSI) | 54.26 |
| Average Volume (20 Days) | 681,793 |
Short Selling Information
The latest short interest is 5.47 million, so 10.83% of the outstanding shares have been sold short.
| Short Interest | 5.47M |
| Short Previous Month | 5.48M |
| Short % of Shares Out | 10.83% |
| Short % of Float | 13.21% |
| Short Ratio (days to cover) | 8.16 |
Income Statement
In the last 12 months, REGENXBIO had revenue of $155.78 million and -$175.57 million in losses. Loss per share was -$3.43.
| Revenue | 155.78M |
| Gross Profit | 128.43M |
| Operating Income | -164.60M |
| Pretax Income | n/a |
| Net Income | -175.57M |
| EBITDA | -148.75M |
| EBIT | -164.60M |
| Loss Per Share | -$3.43 |
Full Income StatementBalance Sheet
The company has $323.30 million in cash and $271.69 million in debt, giving a net cash position of $91.90 million or $1.82 per share.
| Cash & Cash Equivalents | 323.30M |
| Total Debt | 271.69M |
| Net Cash | 91.90M |
| Net Cash Per Share | $1.82 |
| Equity (Book Value) | 213.68M |
| Book Value Per Share | 4.24 |
| Working Capital | 254.21M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$87.89 million and capital expenditures -$2.82 million, giving a free cash flow of -$90.71 million.
| Operating Cash Flow | -87.89M |
| Capital Expenditures | -2.82M |
| Free Cash Flow | -90.71M |
| FCF Per Share | -$1.80 |
Full Cash Flow StatementMargins
Gross margin is 82.44%, with operating and profit margins of -105.66% and -112.70%.
| Gross Margin | 82.44% |
| Operating Margin | -105.66% |
| Pretax Margin | -112.70% |
| Profit Margin | -112.70% |
| EBITDA Margin | -95.49% |
| EBIT Margin | -105.66% |
| FCF Margin | n/a |
Dividends & Yields
REGENXBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.99% |
| Shareholder Yield | -10.99% |
| Earnings Yield | -38.92% |
| FCF Yield | -20.11% |
Analyst Forecast
The average price target for REGENXBIO is $28.50, which is 215.97% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $28.50 |
| Price Target Difference | 215.97% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 50.45% |
| EPS Growth Forecast (5Y) | -32.40% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
REGENXBIO has an Altman Z-Score of -1.78 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.78 |
| Piotroski F-Score | 3 |
